Stock ATHE ALTERITY THERAPEUTICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News Alterity Therapeutics Limited Nasdaq

Equities

ATHE

US02155X2053

Market Closed - Nasdaq
Other stock markets
 21:30:00 17/05/2024 BST 		5-day change 1st Jan Change
2 USD -0.99% Intraday chart for Alterity Therapeutics Limited -0.50% -19.68%
05-08 Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review CI
05-08 Alterity Therapeutics on Track to Complete Phase Two Trial of Lead Drug Candidate in November MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
CI
Alterity Therapeutics on Track to Complete Phase Two Trial of Lead Drug Candidate in November
MT
Alterity Therapeutics Limited Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Diseases
CI
ADRs End Lower, Purple Biotech Ltd. Declines 29%
DJ
ADRs End Lower, Leju Holdings Ltd. Declines 72%
DJ
ADRs End Higher, Lixiang Education Holding Co. Ltd. Climbs 69%
DJ
ADRs Close Lower; VIA Optronics AG Declines 30%
DJ
Top Midday Gainers
MT
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
AQ
Alterity Therapeutics Receives AU$3.9 Million R&D Tax Refund
MT
Alterity Therapeutics : Receives a $3.9 million Research & Development Tax Incentive Refund
PU
Genetic Technologies Appoints CFO
MT
Alterity Therapeutics : Voting ahead of attending the Meeting - Form 6-K
PU
Alterity Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023
CI
Alterity Therapeutics Limited Reports Earnings Results for the Half Year Ended December 30, 2023
CI
Alterity Therapeutics Raises AU$3.3 Million for Clinical Trials; Shares Fall 20%
MT
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review
AQ
Alterity Therapeutics's Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review
CI
Alterity Therapeutics Advances Phase Two Multiple System Atrophy Trial Following Committee Recommendation
MT
Alterity Therapeutics Completes Securities Purchase Plan
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ATH Stock
  4. ATHE Stock
  5. News Alterity Therapeutics Limited